338 related articles for article (PubMed ID: 20959483)
1. Early detection of recurrent breast cancer using metabolite profiling.
Asiago VM; Alvarado LZ; Shanaiah N; Gowda GA; Owusu-Sarfo K; Ballas RA; Raftery D
Cancer Res; 2010 Nov; 70(21):8309-18. PubMed ID: 20959483
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer detection using targeted plasma metabolomics.
Jasbi P; Wang D; Cheng SL; Fei Q; Cui JY; Liu L; Wei Y; Raftery D; Gu H
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1105():26-37. PubMed ID: 30562627
[TBL] [Abstract][Full Text] [Related]
3. Global untargeted and individual targeted plasma metabolomics of breast cancer recurrence modified by hormone receptors.
Yang PJ; Tsai EM; Hou MF; Lee YJ; Wang TN
Breast Cancer; 2024 Jul; 31(4):659-670. PubMed ID: 38652345
[TBL] [Abstract][Full Text] [Related]
4. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS).
Chan EC; Koh PK; Mal M; Cheah PY; Eu KW; Backshall A; Cavill R; Nicholson JK; Keun HC
J Proteome Res; 2009 Jan; 8(1):352-61. PubMed ID: 19063642
[TBL] [Abstract][Full Text] [Related]
5. Detection of human mammaglobin mRNA in serial peripheral blood samples from patients with non-metastatic breast cancer is not predictive of disease recurrence.
Marques AR; Teixeira E; Diamond J; Correia H; Santos S; Neto L; Ribeiro M; Miranda A; Passos-Coelho JL
Breast Cancer Res Treat; 2009 Mar; 114(2):223-32. PubMed ID: 18409061
[TBL] [Abstract][Full Text] [Related]
6. A novel serum metabolome score for breast cancer diagnosis.
Rashed R; Darwish H; Omran M; Belal A; Zahran F
Br J Biomed Sci; 2020 Oct; 77(4):196-201. PubMed ID: 32546046
[TBL] [Abstract][Full Text] [Related]
7. Principal component directed partial least squares analysis for combining nuclear magnetic resonance and mass spectrometry data in metabolomics: application to the detection of breast cancer.
Gu H; Pan Z; Xi B; Asiago V; Musselman B; Raftery D
Anal Chim Acta; 2011 Feb; 686(1-2):57-63. PubMed ID: 21237308
[TBL] [Abstract][Full Text] [Related]
8. Early Breast Cancer Detection Using Untargeted and Targeted Metabolomics.
Wei Y; Jasbi P; Shi X; Turner C; Hrovat J; Liu L; Rabena Y; Porter P; Gu H
J Proteome Res; 2021 Jun; 20(6):3124-3133. PubMed ID: 34033488
[TBL] [Abstract][Full Text] [Related]
9. The Karlsruhe Metabolomics and Nutrition (KarMeN) Study: Protocol and Methods of a Cross-Sectional Study to Characterize the Metabolome of Healthy Men and Women.
Bub A; Kriebel A; Dörr C; Bandt S; Rist M; Roth A; Hummel E; Kulling S; Hoffmann I; Watzl B
JMIR Res Protoc; 2016 Jul; 5(3):e146. PubMed ID: 27421387
[TBL] [Abstract][Full Text] [Related]
10. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
[TBL] [Abstract][Full Text] [Related]
11. Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study.
Tenori L; Oakman C; Morris PG; Gralka E; Turner N; Cappadona S; Fornier M; Hudis C; Norton L; Luchinat C; Di Leo A
Mol Oncol; 2015 Jan; 9(1):128-39. PubMed ID: 25151299
[TBL] [Abstract][Full Text] [Related]
12. Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population.
Hart CD; Vignoli A; Tenori L; Uy GL; Van To T; Adebamowo C; Hossain SM; Biganzoli L; Risi E; Love RR; Luchinat C; Di Leo A
Clin Cancer Res; 2017 Mar; 23(6):1422-1431. PubMed ID: 28082280
[No Abstract] [Full Text] [Related]
13. Elevated serum CA15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer.
Nishimura R; Nagao K; Miyayama H; Matsuda M; Baba K; Matsuoka Y; Yamashita H
Breast Cancer; 2003; 10(3):220-7. PubMed ID: 12955034
[TBL] [Abstract][Full Text] [Related]
14. The combination of four analytical methods to explore skeletal muscle metabolomics: Better coverage of metabolic pathways or a marketing argument?
Bruno C; Patin F; Bocca C; Nadal-Desbarats L; Bonnier F; Reynier P; Emond P; Vourc'h P; Joseph-Delafont K; Corcia P; Andres CR; Blasco H
J Pharm Biomed Anal; 2018 Jan; 148():273-279. PubMed ID: 29059617
[TBL] [Abstract][Full Text] [Related]
15. Using post-column infused internal standard assisted quantitative metabolomics for establishing prediction models for breast cancer detection.
Huang M; Li HY; Liao HW; Lin CH; Wang CY; Kuo WH; Kuo CH
Rapid Commun Mass Spectrom; 2020 Apr; 34 Suppl 1():e8581. PubMed ID: 31693758
[TBL] [Abstract][Full Text] [Related]
16. Targeted serum metabolite profiling and sequential metabolite ratio analysis for colorectal cancer progression monitoring.
Zhu J; Djukovic D; Deng L; Gu H; Himmati F; Abu Zaid M; Chiorean EG; Raftery D
Anal Bioanal Chem; 2015 Oct; 407(26):7857-63. PubMed ID: 26342311
[TBL] [Abstract][Full Text] [Related]
17. Specificity of metabolic colorectal cancer biomarkers in serum through effect size.
Di Giovanni N; Meuwis MA; Louis E; Focant JF
Metabolomics; 2020 Aug; 16(8):88. PubMed ID: 32789702
[TBL] [Abstract][Full Text] [Related]
18. A plasma metabolomic signature discloses human breast cancer.
Jové M; Collado R; Quiles JL; Ramírez-Tortosa MC; Sol J; Ruiz-Sanjuan M; Fernandez M; de la Torre Cabrera C; Ramírez-Tortosa C; Granados-Principal S; Sánchez-Rovira P; Pamplona R
Oncotarget; 2017 Mar; 8(12):19522-19533. PubMed ID: 28076849
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.
Pedersen AC; Sørensen PD; Jacobsen EH; Madsen JS; Brandslund I
Clin Chem Lab Med; 2013 Jul; 51(7):1511-9. PubMed ID: 23403727
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
